Nanologica AB (publ) (NICA.ST)

SEK 1.71

(-0.58%)

Total Debt Summary of Nanologica AB (publ)

  • Nanologica AB (publ)'s latest annual total debt in 2023 was 666 Thousand SEK , down -85.81% from previous year.
  • Nanologica AB (publ)'s latest quarterly total debt in 2024 Q1 was 2.13 Million SEK , up 220.27% from previous quarter.
  • Nanologica AB (publ) reported annual total debt of 4.69 Million SEK in 2022, down -52.08% from previous year.
  • Nanologica AB (publ) reported annual total debt of 9.79 Million SEK in 2021, down -24.47% from previous year.
  • Nanologica AB (publ) reported quarterly total debt of 1.24 Million SEK for 2024 Q2, down -41.63% from previous quarter.
  • Nanologica AB (publ) reported quarterly total debt of 3.47 Million SEK for 2023 Q1, down -25.85% from previous quarter.

Annual Total Debt Chart of Nanologica AB (publ) (2023 - 2012)

Historical Annual Total Debt of Nanologica AB (publ) (2023 - 2012)

Year Total Debt Total Debt Growth
2023 666 Thousand SEK -85.81%
2022 4.69 Million SEK -52.08%
2021 9.79 Million SEK -24.47%
2020 12.96 Million SEK 41.93%
2019 9.13 Million SEK 93.29%
2018 4.72 Million SEK -76.2%
2017 19.85 Million SEK 329.19%
2016 4.62 Million SEK 221.98%
2015 1.43 Million SEK 343.33%
2014 324.1 Thousand SEK 0.0%
2013 - SEK 0.0%
2012 - SEK 0.0%

Peer Total Debt Comparison of Nanologica AB (publ)

Name Total Debt Total Debt Difference
Alligator Bioscience AB (publ) 16.09 Million SEK 95.863%
Ziccum AB (publ) 857 Thousand SEK 22.287%
Modus Therapeutics Holding AB (publ) - SEK -Infinity%
BioArctic AB (publ) 4.97 Million SEK 86.624%
Sprint Bioscience AB (publ) - SEK -Infinity%
Mendus AB (publ) 24.48 Million SEK 97.28%
Genovis AB (publ.) 79.32 Million SEK 99.16%
Intervacc AB (publ) 181 Thousand SEK -267.956%
QuiaPEG Pharmaceuticals Holding AB (publ) 20.61 Million SEK 96.769%
Active Biotech AB (publ) 3 Million SEK 77.8%
Magle Chemoswed Holding AB (publ) 60.3 Million SEK 98.896%
Bio-Works Technologies AB (publ) - SEK -Infinity%
Aptahem AB (publ) 5 Million SEK 86.68%
Vicore Pharma Holding AB (publ) - SEK -Infinity%
Kancera AB (publ) - SEK -Infinity%
Infant Bacterial Therapeutics AB (publ) - SEK -Infinity%
Fluicell AB (publ) - SEK -Infinity%
Saniona AB (publ) 71.4 Million SEK 99.067%
Lipigon Pharmaceuticals AB (publ) - SEK -Infinity%
Biovica International AB (publ) 7.82 Million SEK 91.492%
Spago Nanomedical AB (publ) - SEK -Infinity%
AcouSort AB (publ) - SEK -Infinity%
Xintela AB (publ) - SEK -Infinity%
Abliva AB (publ) 424 Thousand SEK -57.075%
Egetis Therapeutics AB (publ) 108.6 Million SEK 99.387%
Karolinska Development AB (publ) 3.07 Million SEK 78.306%
OncoZenge AB (publ) - SEK -Infinity%
Amniotics AB (publ) 2.58 Million SEK 74.186%
2cureX AB (publ) - SEK -Infinity%
CombiGene AB (publ) - SEK -Infinity%
Asarina Pharma AB (publ) 1 Million SEK 33.4%
Calliditas Therapeutics AB (publ) 979.13 Million SEK 99.932%
Camurus AB (publ) 24.5 Million SEK 97.282%
Corline Biomedical AB - SEK -Infinity%
IRLAB Therapeutics AB (publ) 27.56 Million SEK 97.584%
Isofol Medical AB (publ) - SEK -Infinity%
I-Tech AB - SEK -Infinity%
Hansa Biopharma AB (publ) 866.76 Million SEK 99.923%
Cyxone AB (publ) 858 Thousand SEK 22.378%
ExpreS2ion Biotech Holding AB (publ) 1.71 Million SEK 61.075%
Biosergen AB - SEK -Infinity%
Cantargia AB (publ) - SEK -Infinity%
NextCell Pharma AB - SEK -Infinity%
Xspray Pharma AB (publ) 36.8 Million SEK 98.191%
Elicera Therapeutics AB (publ) - SEK -Infinity%
SynAct Pharma AB 637 Thousand SEK -4.553%
Annexin Pharmaceuticals AB (publ) - SEK -Infinity%
Stayble Therapeutics AB (publ) 850 Thousand SEK 21.647%
LIDDS AB (publ) - SEK -Infinity%
Lipum AB (publ) 1.76 Million SEK 62.181%
BioInvent International AB (publ) 23.24 Million SEK 97.135%
Alzinova AB (publ) 800 Thousand SEK 16.75%
Oncopeptides AB (publ) 106.48 Million SEK 99.375%
Pila Pharma AB (publ) 773.08 Thousand SEK 13.851%
Guard Therapeutics International AB (publ) - SEK -Infinity%
Scandinavian ChemoTech AB (publ) - SEK -Infinity%
Simris Alg AB (publ) 90.74 Million SEK 99.266%
Diamyd Medical AB (publ) 30.67 Million SEK 97.829%
Xbrane Biopharma AB (publ) 231.47 Million SEK 99.712%
Ascelia Pharma AB (publ) 1.06 Million SEK 37.229%
Diagonal Bio AB (publ) - SEK -Infinity%